menu
    • menu
    [{"orgOrder":0,"company":"DreamTec Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ Undisclosed"},{"orgOrder":0,"company":"DreamTec Research","sponsor":"Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"National Children's Hospital, Vietnam","sponsor":"Anabio R&D","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Children's Hospital, Vietnam","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Children's Hospital, Vietnam \/ Anabio R&D","highestDevelopmentStatusID":"1","companyTruncated":"National Children's Hospital, Vietnam \/ Anabio R&D"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"VIETNAM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Helse Stavanger | ADM Protexin","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Edinburgh \/ Helse Stavanger | ADM Protexin","highestDevelopmentStatusID":"1","companyTruncated":"University of Edinburgh \/ Helse Stavanger | ADM Protexin"}]

    Find Clinical Drug Pipeline Developments & Deals for Bacillus Subtilis

    Menu

    Bacillus Subtilis

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Anabio R&D

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Anabio R&D

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of LiveSpo COLON as a Supportive Treatment for Inflammatory Bowel Disease (IBD)

                            Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Inflammatory Bowel Diseases.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            October 15, 2024

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Vietstar Biomedical Research | Thai Binh University of Medicine and Pharmacy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Edinburgh

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of Edinburgh

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Helse Stavanger | ADM Protexin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bacillus Subtilis in Parkinson's Disease

                            Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            July 05, 2024

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Helse Stavanger | ADM Protexin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            National Children's Hospital, Vietnam

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            National Children's Hospital, Vietnam

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Anabio R&D

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infection...

                            Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Respiratory Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Anabio R&D

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Anabio R&D

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Anabio R&D

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Thai Binh University of Medicine and Pharmacy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

                            Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Respiratory Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            April 07, 2023

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Thai Binh University of Medicine and Pharmacy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            DreamTec Research

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            DreamTec Research

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores

                            Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            February 15, 2022

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            DreamTec Research

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            DreamTec Research

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores

                            Details : Bacillus Subtilis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            September 27, 2021

                            Lead Product(s) : Bacillus Subtilis

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth